EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Copeptin as an Early Adjunct to High-Sensitivity Cardiac Troponin I in Initially Troponin-Negative Acute Myocardial Infarction: A Prospective Case–Control Study

Gökay Sülü, Serdar Derya, Mahmut Murat, Mustafa Safa Pepele, Ahmet Burak Avcu, Merve Sülü, Şükrü Gürbüz, Cuma Mertoğlu, Hasan Cengizhan Katırcı, Neslihan Yücel

Journal of Cardiovascular Development and Disease · 2026-11-07 · 13 (11) · 574

DOI: 10.3390/jcdd13110574 ↗
AbstractBibliografische Angaben

Abstract

Early diagnosis of acute myocardial infarction (AMI) remains challenging in patients with initially non-elevated high-sensitivity cardiac troponin I (hs-cTnI). We assessed the diagnostic contribution of copeptin, with endothelin-1 and chemerin as exploratory comparators. This prospective, single-center case–control study included 160 adults with suspected acute coronary syndrome: 40 controls, 40 with unstable angina, 40 with non-ST-elevation myocardial infarction (NSTEMI), and 40 with ST-elevation myocardial infarction (STEMI). Samples were obtained at presentation, and diagnoses were adjudicated blinded to investigational biomarkers. Twelve of the 80 AMI cases had initially non-elevated hs-cTnI (7 STEMI; 5 NSTEMI). Copeptin was positive in 8/12 and the three-marker panel in 9/12. Among the five initially troponin-negative NSTEMI cases, all positive on repeat hs-cTnI testing, copeptin was positive in 4/5 (80.0%; 95% confidence interval, 28.4–99.5%). The hs-cTnI OR copeptin strategy increased sensitivity from 85.0% to 95.0%, while specificity among controls decreased from 95.0% to 62.5%. Adding the biomarkers to a clinical model containing hs-cTnI changed the apparent area under the curve from 0.961 to 0.965, without significantly improving model fit (likelihood-ratio p = 0.718). These findings may support evaluating adjunctive copeptin within contemporary accelerated troponin pathways.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →